« Return to News | Drug Sponsors | CROs/Service Providers

Almirall, Quintiles sign long-term commercial U.K. partnership

Monday, July 30, 2012 10:52 AM

Global pharmaceutical company Almirall and Quintiles, a fully integrated biopharmaceutical services company, have reached a long-term strategic partnership agreement to promote Almirall’s respiratory portfolio in the U.K. commencing with a new, long-acting antimuscarinic (LAMA) delivered via an innovative, multi-dose inhaler for the treatment of chronic obstructive pulmonary disease (COPD).

After the Committee for Medicinal Products for Human Use (CHMP) of the EMA issued a positive opinion for the regulatory approval of Almirall’s new LAMA as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD on May 28, 2012, the European Commission finally approved the medicine on July 24.

“We are proud to bring the first product in a truly innovative respiratory franchise to the U.K. market. Our long-term alignment with Quintiles will help us to ensure that new therapeutic options are made available for COPD patients throughout the U.K.,” said Carlos Gallardo, general manager, Almirall U.K.

This strategic partnership deepens the relationship between the two organizations: Quintiles conducted part of the clinical study program in COPD and provides commercialization services to Almirall in multiple European countries.

The FDA also issued final positive feedback on Almirall’s first product in COPD on July 24.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

May 13

New partnership of Parkinson's groups aims to unify the message about importance of trial participation

Using study startup checklists can improve site-sponsor communication, relationships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

INC Research, PPD, inVentiv named top CROs
Yet most CROs slipping in ability to manage site relationships

R&D cuts by sponsors spur more collaboration, innovation
New strategies share pipeline activity costs

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

20 innovators changing the face of the clinical trials industry
The CenterWatch Monthly honors individuals, teams and companies for their forward-thinking ideas and their ability to implement them.

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.